| 2.19 -0.02 (-0.9%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.72  |
1-year : | 3.17 |
| Resists | First : | 2.32 |
Second : | 2.72 |
| Pivot price | 1.98  |
|||
| Supports | First : | 1.97 |
Second : | 1.75 |
| MAs | MA(5) : | 2.1 |
MA(20) : | 1.97 |
| MA(100) : | 2.78 |
MA(250) : | 3.18 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 94.6 |
D(3) : | 89 |
| RSI | RSI(14): 54.7 |
|||
| 52-week | High : | 9.07 | Low : | 1.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CNTN ] has closed below upper band by 2.2%. Bollinger Bands are 50.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.23 - 2.24 | 2.24 - 2.25 |
| Low: | 2.11 - 2.12 | 2.12 - 2.13 |
| Close: | 2.17 - 2.19 | 2.19 - 2.21 |
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
Sat, 22 Aug 2026
Canton Strategic Holdings (MEX:CNTN) Cyclically Adjusted PB Ratio : (As of Aug. 23, 2026) - GuruFocus
Fri, 14 Aug 2026
Canton Strategic Posts $1.5 Million Q2 Revenue From Canton Network Operations - Quiver Quantitative
Fri, 14 Aug 2026
Canton Strategic Holdings (NASDAQ: CNTN) posts first Canton Network revenue amid sizable Q2 2026 loss - Stock Titan
Fri, 14 Aug 2026
Canton Strategic Holdings (CNTN) posts $66.6M loss amid big Canton Coin bet - Stock Titan
Fri, 14 Aug 2026
Canton Strategic Holdings, Inc. Q2 2026: Revenue $1.5M, EPS $(0.09) — 10-Q Summary - TradingView
Fri, 14 Aug 2026
Canton Strategic's locking-as-a-service offering generated about $1.3M - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 77 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 17.5 (%) |
| Held by Institutions | 21.9 (%) |
| Shares Short | 7,780 (K) |
| Shares Short P.Month | 4,680 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11.7 % |
| Return on Equity (ttm) | -34.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -6.09 |
| PEG Ratio | 0 |
| Price to Book value | 0.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|